Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Net Cash Flow: 2019-2024

Historic Net Cash Flow for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Dec 2024 value amounting to -$127.6 million.

  • Tarsus Pharmaceuticals' Net Cash Flow rose 429.09% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.9 million, marking a year-over-year decrease of 20.73%. This contributed to the annual value of -$127.6 million for FY2024, which is 183.22% down from last year.
  • Per Tarsus Pharmaceuticals' latest filing, its Net Cash Flow stood at -$127.6 million for FY2024, which was down 183.22% from $153.3 million recorded in FY2023.
  • Tarsus Pharmaceuticals' 5-year Net Cash Flow high stood at $153.3 million for FY2023, and its period low was -$127.6 million during FY2024.
  • In the last 3 years, Tarsus Pharmaceuticals' Net Cash Flow had a median value of -$99.7 million in 2022 and averaged -$24.7 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Net Cash Flow crashed by 3,231.39% in 2022 and then surged by 253.79% in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' Net Cash Flow (Yearly) stood at $110.2 million in 2020, then slumped by 97.11% to $3.2 million in 2021, then plummeted by 3,231.39% to -$99.7 million in 2022, then skyrocketed by 253.79% to $153.3 million in 2023, then crashed by 183.22% to -$127.6 million in 2024.